Lumena Files For $75 Million IPO To Forward Liver Disease Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech investment momentum may have slowed recently, but the San Diego biotech is hoping the IPO window remains open. The company is developing a compound shelved by Pfizer to address high cholesterol; LUM001 currently is in Phase II for a set of cholestatic liver diseases.